Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
Provided By GlobeNewswire
Last update: Nov 7, 2024
BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies
BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model
Read more at globenewswire.comNASDAQ:BOLT (2/21/2025, 8:04:02 PM)
0.488
-0.02 (-4.29%)
Find more stocks in the Stock Screener
